Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis

Therapeutic Drug Monitoring

Volumn 33, Issue 3, 2011, Pages 350-354

  Pranger, Arianna D ^a   Kosterink, Jos G W ^a   Van Altena, Richard ^a   Aarnoutse, Rob E ^b   Van Der Werf, Tjip S ^a   Uges, Donald R A ^a   Alffenaar, Jan Willem C ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Limited sampling; Moxifloxacin; Therapeutic drug monitoring; Tuberculosis

Indexed keywords

MOXIFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; HUMAN; LIQUID CHROMATOGRAPHY; MONTE CARLO METHOD; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ADULT; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; TREATMENT FAILURE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 80051783211     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821b793c     Document Type: Article

References (30)

1. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother. 2010;54:1484-1491.
2. Ginsburg AS, Grosset JH, Bishai WR. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis. 2003;3:432-442. (Pubitemid 36791119)
3. van den Boogaard J, Kibiki GS. New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob Agents Chemother 2009;53:849-862.
4. Nuermberger EL, Yoshimatsu T, Tyagi S. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med. 2004;169:421-426. (Pubitemid 38134824)
5. Nuermberger EL, Yoshimatsu T, Tyagi S. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med. 2004;170:1131-1134. (Pubitemid 39488628)
6. Conde MB, Efron A, Loredo C. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009 ;373:1183-1189.
7. Rustomjee R, Lienhardt C, Kanyok T. A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis. 2008;12:128-138. (Pubitemid 351212403)
8. Burman WJ, Goldberg S, Johnson JL. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174:331-338. (Pubitemid 44156613)
9. Dorman SE, Johnson JL, Goldberg S. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med. 2009;180:273-280.
10. Poissy J, Aubry A, Fernandez C. Should moxifloxacin be used for the treatment of XDR-TB? An answer from the murine model. Antimicrob Agents Chemother. 54:4765-4771.
11. Shandil RK, Jayaram R, Kaur P. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother. 2007;51:576-582. (Pubitemid 46185275)
12. Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46:669-683.
13. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis. 2004;23:243-255. (Pubitemid 38669936)
14. Valerio G, Bracciale P, Manisco V. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother. 2003;15:66-70. (Pubitemid 36355891)
15. Codecasa LR, Ferrara G, Ferrarese M. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med. 2006;100:1566-1572. (Pubitemid 44109116)
16. Gumbo T, Louie A, Deziel MR. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis. 2004;190:1642-1651. (Pubitemid 39411014)
17. Nijland HM, Ruslami R, Suroto AJ. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis. 2007;45:1001-1007. (Pubitemid 47580349)
18. Weiner M, Burman W, Luo CC. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother. 2007;51:2861-2866. (Pubitemid 47206223)
19. Stass H, Kubitza D, Schuhly U. Pharmacokinetics, safety and tolerability of moxifloxacin, a novel 8-methoxyfluoroquinolone, after repeated oral administration. Clin Pharmacokinet. 2001;40(suppl 1):1-9. (Pubitemid 32295676)
20. van Klingeren B, Dessens-Kroon M, van der Laan T, et al. Drug susceptibility testing of Mycobacterium tuberculosis complex by use of a high-throughput, reproducible, absolute concentration method. J Clin Microbiol. 2007;45:2662-2668. (Pubitemid 47295501)
21. Pranger AD, Alffenaar JW, Wessels AM. Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method. J Anal Toxicol. 2010;34:135-141.
22. Proost JH, Eleveld DJ. Performance of an iterative two-stage Bayesian technique for population pharmacokinetic analysis of rich data sets. Pharm Res. 2006;23:2748-2759. (Pubitemid 44885363)
23. Peloquin CA, Hadad DJ, Molino LP. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852-857. (Pubitemid 351358362)
24. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 2000;19:453-473. (Pubitemid 30126878)
25. Pranger AD, van Altena R, Aarnoutse RE. Evaluation of Moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. February 10, 2011 [epub ahead of print].
26. Jelliffe RW, Iglesias T, Hurst AK. Individualising gentamicin dosage regimens. A comparative review of selected models, data fitting methods and monitoring strategies. Clin Pharmacokinet. 1991;21:461-478.
27. Sacco F, Spezzaferro M, Amitrano M, et al. Efficacy of four different moxifloxacin-based triple therapies for first-line H. pylori treatment. Dig Liver Dis. 2010;42:110-114.
28. Demolis JL, Kubitza D, Tenneze L. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther. 2000;68:658-666. (Pubitemid 32059992)
29. Viskin S, Justo D, Halkin A. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis. 2003;45:415-427. (Pubitemid 36403114)
30. Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm. 2008;65: 1029-1038. (Pubitemid 351768736)